Skip to main content

Remote Job Finders (RJF)

Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study

Amgen is awaiting another Phase 3 readout for the investigational Sjögren’s disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an FDA application.

Pharmas face off for manufacturing talent amidst reshoring efforts

As pharmas reshore manufacturing, they’re squaring off with each other to find the right personnel to staff up their plants. That task is challenging given the limited talent pool, difficulty filling critical roles and, in some cases, competition from data centers.
Scroll to top